Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 17,092	$ 2,776
Accounts receivable	443	898
Prepaid expenses and other current assets	702	336
Total current assets	18,237	4,010
Property and equipment, net	488	594
TOTAL ASSETS	18,725	4,604
Current liabilities:
Accounts payable	2,944	3,208
Accrued expenses	2,993	3,670
Senior secured convertible debt, net	7,890
Total current liabilities	13,827	6,878
Long-term debt	1,134
TOTAL LIABILITIES	14,961	6,878
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of September 30, 2020, and December 31, 2019; 22,380,351 and 14,887,999 shares issued as of September 30, 2020 and December 31, 2019, respectively; 22,379,499 and 14,887,147 shares outstanding as of September 30, 2020 and December 31, 2019, respectively	3	1
Additional paid-in capital	250,843	222,403
Treasury stock, at cost; 852 shares of common stock as of September 30, 2020 and December 31, 2019, respectively	(11)	(11)
Accumulated deficit	(271,034)	(248,630)
Total Vaccinex, Inc. stockholders’ deficit	(20,199)	(26,237)
Noncontrolling interests	23,963	23,963
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	3,764	(2,274)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 18,725	$ 4,604